About Organovo Holdings
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ONVO
- Previous Close: $2.97
- 50 Day Moving Average: $3.51
- 200 Day Moving Average: $3.58
- 52-Week Range: $2.00 - $4.99
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.62
- P/E Growth: 0.00
- Market Cap: $N/A
- Beta: 3.15
- Net Margins: -911.80%
- Return on Equity: -60.17%
- Return on Assets: -55.62%
Companies Related to Organovo Holdings:
- Current Ratio: 16.20%
- Quick Ratio: 16.13%
What is Organovo Holdings' stock symbol?
Organovo Holdings trades on the NASDAQ under the ticker symbol "ONVO."
Where is Organovo Holdings' stock going? Where will Organovo Holdings' stock price be in 2017?
4 brokerages have issued 12 month price objectives for Organovo Holdings' shares. Their forecasts range from $4.50 to $15.00. On average, they anticipate Organovo Holdings' stock price to reach $7.25 in the next year.
When will Organovo Holdings announce their earnings?
Organovo Holdings is scheduled to release their next quarterly earnings announcement on Thursday, February, 9th 2017.
Who owns Organovo Holdings stock?
Organovo Holdings' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (0.00%), ARK Investment Management LLC (0.00%), FIL Ltd (0.00%), First Republic Investment Management Inc. (0.00%), Trent Capital Management Inc. NC (0.00%) and Metropolitan Life Insurance Co. NY (0.00%). Company insiders that own Organovo Holdings stock include Eric David and Keith Murphy.
Who sold Organovo Holdings stock? Who is selling Organovo Holdings stock?
Organovo Holdings' stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY. Company insiders that have sold Organovo Holdings stock in the last year include Eric David and Keith Murphy.
Who bought Organovo Holdings stock? Who is buying Organovo Holdings stock?
Organovo Holdings' stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Trent Capital Management Inc. NC, First Republic Investment Management Inc., Ladenburg Thalmann Financial Services Inc., Bessemer Group Inc., State Street Corp, Private Advisor Group LLC and Tudor Investment Corp Et Al.
How do I buy Organovo Holdings stock?
Shares of Organovo Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Organovo Holdings stock cost?
One share of Organovo Holdings stock can currently be purchased for approximately $2.97.